BEDFORD, Mass.–(BUSINESS WIRE)–September 20, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, today announced a preview of clinical data that will be presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO 2017), which will take place September 24-27 in San Diego. The presentations will provide new insights on the clinical and quality of life benefits of the company’s novel absorbable hydrogel spacing technology in providing protection during radiation therapy.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920006026/en/
SpaceOAR hydrogel separates the prostate and rectum during radiation treatment (Photo: Business Wire)
SpaceOAR® hydrogel, Augmenix’s lead product, is FDA cleared and is designed to protect the rectum in men undergoing radiation therapy for prostate cancer.
“While significant improvements have been made in the delivery of radiation therapy, the need to reliably target cancerous tissues while minimizing injury to healthy surrounding organs remains of critical importance. Augmenix is dedicated to bringing meaningful solutions that meet this ever-present need,” said John Pedersen, CEO, Augmenix. “We look forward to several presentations at ASTRO 2017 which demonstrate the benefits of hydrogel technology to improve the lives of patients receiving radiation therapy.”
Augmenix will have a significant presence at ASTRO 2017. Most notably, results from the first prospective study evaluating the efficacy of SpaceOAR hydrogel in patients undergoing high-dose stereotactic body radiation therapy (SBRT) for prostate cancer will be presented as a late-breaking clinical trial on Tuesday, September 26. Additionally, the first 5-year quality of life data results in prostate cancer patients treated with SpaceOAR hydrogel will also be unveiled on Tuesday in an oral presentation, demonstrating significant bowel and sexual function benefits. A didactic industry-sponsored panel discussion on the present and future role of hydrogel spacing in the treatment of prostate cancer – led by renowned radiation oncologists from around the world – will occur on Monday, September 25.
Following is a detailed schedule of the company’s events in chronological order, all of which will take place at the San Diego Convention and Exhibition Center (times are U.S. Pacific Daylight Time).
Sunday, September 24
The following poster presentations will take place from 1:15 p.m. – 2:45 p.m. in the Poster Hall:
- Poster Presentation (No : 2559): Dosimetry for Organs at Risk With and Without Use of Perirectal Hydrogel Spacer in Prostate Cancer Patients Treated With SBRT
- Presented by: Daniel B. Fried, MD, PhD, MPH
- Poster Presentation (No : 2572): A Pilot Study – The Role of Radio-Opaque Hydrogel Tissue Marker in the Treatment of Postprostatectomy Intensity Modulated Radiation Therapy
- Presented by Huong Ho, DO
- Poster Presentation (No : 3383): Updated Retrospective Dose Volume Histogram Analysis of High Dose Rate Prostate Brachytherapy Patients With Hydrogel Spacer Implantation
- Presented by Sean Cavanaugh, MD
Monday, September 25
- Industry-Expert Theatre: Present and Future Role of Hydrogel Spacing in the Treatment of Prostate Cancer – 3 & 5 Year QOL Evidence and Stereotactic Body Radiation Therapy (SBRT) Experience
- Time/Location: 12:30 p.m. – 1:30 p.m. Exhibit Hall – Theatre 1
- Speakers: Robert Timmerman, MD, Professor of Radiation Oncology and Neurology at the University of Texas Southwestern Medical Center in Dallas; Michael Zelefsky, MD, Professor of Radiation Oncology, Vice-Chair of the Department of Radiology and Chief of the Brachytherapy Service at Memorial Sloan-Kettering Cancer Center in New York City; Daniel Hamstra, MD, PhD, Clinical Director and Professor at William Beaumont Oakland University Medical School, Department of Radiation Oncology, Beaumont Health, Dearborn, MI; and Prof. Dr. Michael Pinkawa, Director of the Department of Radiation Oncology, MediClin Robert Janker Klinik in Bonn, Germany.
- Moderator: Rodney Ellis, MD, Vice Chair for Clinical Affairs at the University Hospitals Cleveland Medical Center and Associate Professor, Radiation Oncology at Case Western Reserve University in Cleveland, OH.
- Poster Presentation (No : 3613): The Rectal Dosimetric Effects of Perirectal Hydrogel Spacers in Men Undergoing Prostate Stereotactic Body Radiation Therapy (SBRT)
- Time/Location: 4:15 p.m. – 5:45 p.m. Poster Hall
- Presenter: Shaan Kataria, MD
Tuesday, September 26
- Late-Breaking Abstracts Special Session (SS 22): Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer
- Time/Location: 7:45 a.m. – 9 a.m. Room 5A
- Presenter: Michael Folkert, MD
- ePoster Presentation (No: 1083): Quality of Life after Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year Results
- Time/Location: 1:12 p.m. Room 5B
- Presenter: Michael Pinkawa, MD, PhD
- Poster Presentation (No : 2869): Biodegradable Hydrogel Spacer Injection for Contralateral Submandibular Gland Sparing in Radiation Therapy for Head and Neck Cancers
- Time/Location: 2:45 p.m. – 4:15 p.m. Poster Hall
- Presenter: Avani Rao, MD
- Poster Presentation (No : 2435): Novel Use of a Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum for Radiation Therapy for Pancreatic Cancer
- Time/Location: 4:45 p.m. – 6:15 p.m. Poster Hall
- Presenter: Avani Rao, MD
Augmenix will be exhibiting in the Main Exhibit Hall B2-G at booth 2917 throughout the duration of the conference.
All clinical data results are embargoed until the time of each scientific presentation.
ABOUT SPACEOAR® HYDROGEL
Radiation therapy in the treatment of prostate cancer can cause unintended radiation injury to adjacent healthy tissue (organs at risk). This injury can lead to a range of bowel, urinary and sexual symptoms that can affect patient health and quality of life during prostate radiotherapy, and for years afterward. In recent years, radiation oncologists have considered use of “spacing” techniques to reduce the risk of radiation injury to surrounding tissue during radiotherapy. SpaceOAR hydrogel is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR hydrogel to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR hydrogel is injected as a liquid into the space between the prostate and rectum where it pushes the structures apart and then solidifies into a soft hydrogel. The hydrogel remains stable for three months during radiation therapy then liquefies and is completely absorbed by the body. See the Instructions for Use for complete information on potential risks, warnings and precautions.
ABOUT AUGMENIX, INC.
Augmenix, Inc. is a privately held U.S. company based in the Boston, Massachusetts area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. Focusing initially on protection during prostate radiation therapy, Augmenix next-generation products will address spacing and marking applications throughout the body to improve radiotherapy and interventional oncology procedure outcomes. The company’s lead product, SpaceOAR System, is FDA cleared and is currently being used in the majority of leading cancer centers in the United States. It is also CE marked, approved in Australia and Japan, and licensed in Canada. SpaceOAR is a registered trademark of Augmenix, Inc. More information about Augmenix and the SpaceOAR hydrogel can be found at http://www.Augmenix.com.
EILEEN GARDNER, RN, 781-902-1625